Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double-Duty mRNA vaccine targets RSV and hMPV in early trial

NCT ID NCT06237296

Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental mRNA vaccine designed to protect against two respiratory viruses: RSV and hMPV. Healthy adults aged 18 to 49 and 60 years and older received a single injection of the vaccine at different doses. The main goals were to check safety and measure the immune response, not yet to prove it prevents illness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mRNA vaccine targeting RSV and hMPV viruses
What this could lead to
If successful, this could lead to a single vaccine that protects against two common respiratory viruses, reducing severe lung infections in older adults.
What could go wrong
This is an early Phase 1 trial focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

558 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Informed consent form (ICF) has been signed and dated Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: -Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives. --The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers Metapneumovirus infection Respiratory syncytial virus infection

Contacts and locations

Locations

  • Advanced Clinical Research- Site Number : 8400005

    Meridian, Idaho, 83642, United States

  • Charlottesville Medical Research Center Winding River - Site Number : 8400002

    Charlottesville, Virginia, 22911, United States

  • Coastal Carolina Research Center- Site Number : 8400001

    North Charleston, South Carolina, 29405, United States

  • Investigational Site Number : 0360001

    Camberwell, Victoria, 3124, Australia

  • Investigational Site Number : 0360002

    Botany, New South Wales, 2019, Australia

  • Investigational Site Number : 0360003

    Kanwal, New South Wales, 2259, Australia

  • Investigational Site Number : 0360004

    Sydney, New South Wales, 2035, Australia

  • Investigational Site Number : 0360005

    Morayfield, Queensland, 4506, Australia

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, 2148, Australia

  • Investigational Site Number : 0360007

    Canberra, 2617, Australia

  • Investigational Site Number : 0360008

    Herston, Queensland, 4006, Australia

  • Meridian Clinical Research- Site Number : 8400007

    Binghamton, New York, 13905, United States

  • Velocity Clinical Research, Sioux City Site Number : 8400017

    Sioux City, Iowa, 51106, United States

  • Velocity Clinical Research- New Orleans Site Number : 8400016

    New Orleans, Louisiana, 70119, United States

  • Velocity Clinical Research- Site Number : 8400012

    Cleveland, Ohio, 44122, United States

  • Velocity Clinical Research-Hallandale Beach- Site Number : 8400013

    Hallandale, Florida, 33009, United States

  • Velocity Gardena Site Number : 8400011

    Gardena, California, 90247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.